	Drug	Level	Subtype	Alteration
0	Pembrolizumab	1	All Solid Tumors	Microsatellite Instability-High
1	Nivolumab	1	Colorectal Cancer	Microsatellite Instability-High
2	Tazemetostat	4	Diffuse Large B-Cell Lymphoma	Oncogenic Mutations
3	Dasatinib, Imatinib	1	Acute Lymphoid Leukemia	BCR-ABL1 Fusion
4	Nilotinib, Dasatinib, Imatinib	1	Chronic Myelogenous Leukemia	BCR-ABL1 Fusion
5	Vandetanib	3A	Non-Small Cell Lung Cancer	Fusions
6	Cabozantinib	2A	Non-Small Cell Lung Cancer	Fusions
7	LOXO-195	4	All Tumors	G696A
8	Larotrectinib, Entrectinib	3A	All Solid Tumors	Fusions
9	LOXO-195	4	All Tumors	G623R
10	Everolimus	2A	CNS Cancer	Oncogenic Mutations
11	Everolimus	2A	Renal Cell Carcinoma	Oncogenic Mutations
12	Imatinib	2A	Melanoma	D816H
13	Sunitinib, Sorafenib	2A	Thymic Tumor	D816G
14	Imatinib	2A	Melanoma	D816F
15	Sunitinib, Sorafenib	2A	Thymic Tumor	D816H
16	Imatinib	2A	Melanoma	D816G
17	Imatinib	2A	Melanoma	V654A
18	Avapritinib, DCC-2618	4	Gastrointestinal Stromal Tumor	D816A
19	Imatinib	2A	Melanoma	D816A
20	Sunitinib, Sorafenib	2A	Thymic Tumor	Oncogenic Mutations
21	Imatinib	2A	Melanoma	Oncogenic Mutations
22	Sunitinib, Sorafenib	2A	Thymic Tumor	D816V
23	Avapritinib, DCC-2618	4	Gastrointestinal Stromal Tumor	D816H
24	Imatinib	2A	Melanoma	T670I
25	Regorafenib, Imatinib, Sunitinib	1	Gastrointestinal Stromal Tumor	Oncogenic Mutations
26	Avapritinib, DCC-2618	4	Gastrointestinal Stromal Tumor	D816F
27	Sunitinib, Sorafenib	2A	Thymic Tumor	D816A
28	Sunitinib, Sorafenib	2A	Thymic Tumor	T670I
29	Sunitinib, Sorafenib	2A	Thymic Tumor	D816Y
30	Regorafenib, Sunitinib	1	Gastrointestinal Stromal Tumor	T670I
31	Sunitinib, Sorafenib	2A	Thymic Tumor	Exon 17 mutations
32	Avapritinib, DCC-2618	4	Gastrointestinal Stromal Tumor	D816Y
33	Imatinib	2A	Melanoma	D816Y
34	Imatinib	2A	Melanoma	Exon 17 mutations
35	Sunitinib, Sorafenib	2A	Thymic Tumor	D816F
36	Avapritinib, DCC-2618	4	Gastrointestinal Stromal Tumor	D816N
37	Avapritinib, DCC-2618	4	Gastrointestinal Stromal Tumor	D816V
38	Imatinib	2A	Melanoma	D816V
39	Avapritinib, DCC-2618	4	Gastrointestinal Stromal Tumor	D816G
40	Regorafenib	1	Gastrointestinal Stromal Tumor	Exon 17 mutations
41	Imatinib	2A	Melanoma	D816N
42	Regorafenib, Sunitinib	1	Gastrointestinal Stromal Tumor	V654A
43	Sorafenib	2A	Gastrointestinal Stromal Tumor	Exon 17 mutations
44	Sunitinib, Sorafenib	2A	Thymic Tumor	D816E
45	Sunitinib, Sorafenib	2A	Thymic Tumor	D816N
46	Sunitinib, Sorafenib	2A	Thymic Tumor	V654A
47	Imatinib	2A	Melanoma	D816E
48	Avapritinib, DCC-2618	4	Gastrointestinal Stromal Tumor	D816E
49	Larotrectinib, Entrectinib	3A	All Solid Tumors	Fusions
50	Rucaparib, Niraparib	1	Ovarian Cancer	Oncogenic Mutations
51	Olaparib	2A	Ovarian Cancer	Oncogenic Mutations
52	Abemaciclib, Palbociclib	2A	Dedifferentiated Liposarcoma	Amplification
53	Abemaciclib, Palbociclib	2A	Well-Differentiated Liposarcoma	Amplification
54	LOXO-195	4	All Tumors	G595R
55	LOXO-195	4	All Tumors	G667C
56	Larotrectinib, Entrectinib	3A	All Solid Tumors	Fusions
57	Sorafenib	3A	Histiocytosis	Oncogenic Mutations
58	Sorafenib	3A	Non-Small Cell Lung Cancer	Oncogenic Mutations
59	Everolimus	2A	CNS Cancer	Oncogenic Mutations
60	AZD5363	3A	Endometrial Cancer	E17K
61	AZD5363	3A	Breast Cancer	E17K
62	AZD5363	3A	Ovarian Cancer	E17K
63	Enasidenib	1	Acute Myeloid Leukemia	R140Q
64	Enasidenib	1	Acute Myeloid Leukemia	R172S
65	Enasidenib	1	Acute Myeloid Leukemia	R172M
66	Enasidenib	1	Acute Myeloid Leukemia	R172K
67	Enasidenib	1	Acute Myeloid Leukemia	R172G
68	Buparlisib, Serabelisib, Alpelisib + Fulvestrant, Copanlisib, GDC-0077, Taselisib + Fulvestrant, Alpelisib, Buparlisib + Fulvestrant, Taselisib	3A	Breast Cancer	Oncogenic Mutations
69	Ivosidenib	3A	Acute Myeloid Leukemia	R132Q
70	Ivosidenib	3A	Acute Myeloid Leukemia	R132S
71	Ivosidenib	3A	Acute Myeloid Leukemia	R132H
72	Ivosidenib	3A	Acute Myeloid Leukemia	R132G
73	Ivosidenib	3A	Acute Myeloid Leukemia	R132C
74	DS-3032b, RG7112	3A	Liposarcoma	Amplification
75	Regorafenib, Panitumumab, Cetuximab	1	Colorectal Cancer	Wildtype
76	Panitumumab, Cetuximab	R1	Colorectal Cancer	Oncogenic Mutations
77	Binimetinib, Trametinib	4	Non-Small Cell Lung Cancer	Oncogenic Mutations
78	LY3214996, KO-947, GDC-0994	4	All Tumors	Oncogenic Mutations
79	Temsirolimus, Everolimus	4	Renal Clear Cell Carcinoma	S2215F
80	Temsirolimus, Everolimus	4	Renal Clear Cell Carcinoma	L2230V
81	Temsirolimus, Everolimus	4	Renal Clear Cell Carcinoma	F1888L
82	Temsirolimus, Everolimus	4	Renal Clear Cell Carcinoma	T1977K
83	Everolimus	3A	Bladder Cancer	E2014K
84	Temsirolimus, Everolimus	4	Renal Clear Cell Carcinoma	C1483F
85	AZD9496, Fulvestrant	3A	Breast Cancer	Oncogenic Mutations
86	Binimetinib, Binimetinib + Ribociclib	3A	Melanoma	Oncogenic Mutations
87	Selumetinib + Radioiodine Uptake Therapy	3A	Thyroid Cancer	Oncogenic Mutations
88	Panitumumab, Cetuximab	R1	Colorectal Cancer	Oncogenic Mutations
89	Rucaparib, Niraparib	1	Ovarian Cancer	Oncogenic Mutations
90	Olaparib	2A	Ovarian Cancer	Oncogenic Mutations
91	BGJ-398, AZD4575, JNJ-42756493, Debio1347	3A	Bladder Cancer	Fusions
92	BGJ-398, AZD4575, JNJ-42756493, Debio1347	3A	Cholangiocarcinoma	Fusions
93	Cisplatin	3A	Bladder Cancer	Oncogenic Mutations
94	BGJ-398, JNJ-42756493, AZD-4575, Debio1347	3A	Bladder Cancer	K650E
95	BGJ-398, JNJ-42756493, AZD-4575, Debio1347	3A	Bladder Cancer	S249C
96	BGJ-398, JNJ-42756493, AZD-4575, Debio1347	3A	Bladder Cancer	S371C
97	BGJ-398, JNJ-42756493, AZD-4575, Debio1347	3A	Bladder Cancer	Y373C
98	AZD4547, JNJ-42756493, BGJ398, Debio1347	3A	Bladder Cancer	Fusions
99	BGJ-398, JNJ-42756493, AZD-4575, Debio1347	3A	Bladder Cancer	K650R
100	BGJ-398, JNJ-42756493, AZD-4575, Debio1347	3A	Bladder Cancer	K650N
101	BGJ-398, JNJ-42756493, AZD-4575, Debio1347	3A	Bladder Cancer	K650Q
102	BGJ-398, JNJ-42756493, AZD-4575, Debio1347	3A	Bladder Cancer	K650M
103	BGJ-398, JNJ-42756493, AZD-4575, Debio1347	3A	Bladder Cancer	K650T
104	BGJ-398, JNJ-42756493, AZD-4575, Debio1347	3A	Bladder Cancer	R248C
105	BGJ-398, JNJ-42756493, AZD-4575, Debio1347	3A	Bladder Cancer	G370C
106	BGJ-398, JNJ-42756493, AZD-4575, Debio1347	3A	Bladder Cancer	G380R
107	AZD4547, JNJ-42756493, BGJ398, Debio1347	3A	Lung Squamous Cell Carcinoma	Amplification
108	PF-03084014	4	All Tumors	Gain-of-function Mutations
109	Trastuzumab	1	Esophagogastric Cancer	Amplification
110	Neratinib	3A	Non-Small Cell Lung Cancer	Oncogenic Mutations
111	Neratinib	3A	Breast Cancer	Oncogenic Mutations
112	AP32788	4	Non-Small Cell Lung Cancer	Exon 20 insertions
113	AP32788	4	Non-Small Cell Lung Cancer	Exon 20 insertions/deletions
114	Lapatinib + Trastuzumab, Pertuzumab + Trastuzumab, Ado-Trastuzumab Emtansine, Lapatinib, Trastuzumab	1	Breast Cancer	Amplification
115	Dabrafenib + Trametinib	1	Non-Small Cell Lung Cancer	V600D
116	Vemurafenib, Dabrafenib	2A	Non-Small Cell Lung Cancer	V600M
117	RTK-Inhibitor + Trametinib	4	Non-Small Cell Lung Cancer	G466A
118	RTK-Inhibitor + Trametinib	4	Colorectal Cancer	D594A
119	RTK-Inhibitor + Trametinib	4	Colorectal Cancer	F595L
120	Vemurafenib, Dabrafenib	2A	Non-Small Cell Lung Cancer	V600G
121	Dabrafenib + Lapatinib	4	Thyroid Cancer	V600K
122	Vemurafenib, Dabrafenib, Dabrafenib + Trametinib, Vemurafenib + Cobimetinib, Trametinib	1	Melanoma	V600M
123	RTK-Inhibitor + Trametinib	4	Non-Small Cell Lung Cancer	G466E
124	Vemurafenib, Dabrafenib, Dabrafenib + Trametinib, Vemurafenib + Cobimetinib, Trametinib	1	Melanoma	V600K
125	Vemurafenib, Dabrafenib	2A	Non-Small Cell Lung Cancer	V600E
126	RTK-Inhibitor + Trametinib	4	Colorectal Cancer	G466V
127	Dabrafenib + Lapatinib	4	Thyroid Cancer	V600E
128	RTK-Inhibitor + Trametinib	4	Non-Small Cell Lung Cancer	N581I
129	Vemurafenib	1	Histiocytosis	V600M
130	Trametinib	4	Melanoma	G469R
131	RTK-Inhibitor + Trametinib	4	Non-Small Cell Lung Cancer	N581S
132	Cobimetinib, Trametinib	3A	Ovarian Cancer	Fusions
133	Trametinib	3A	Melanoma	L597Q
134	Trametinib	3A	Melanoma	L597R
135	Vemurafenib	1	Histiocytosis	V600R
136	Vemurafenib, Dabrafenib, Dabrafenib + Trametinib, Vemurafenib + Cobimetinib, Trametinib	1	Melanoma	V600G
137	Vemurafenib	1	Histiocytosis	V600D
138	Vemurafenib, Dabrafenib	2A	Non-Small Cell Lung Cancer	V600D
139	Cobimetinib, Trametinib	3A	Melanoma	Fusions
140	Vemurafenib	1	Histiocytosis	V600E
141	Trametinib	4	Melanoma	p61BRAF-V600E
142	RTK-Inhibitor + Trametinib	4	Colorectal Cancer	D594N
143	RTK-Inhibitor + Trametinib	4	Non-Small Cell Lung Cancer	D594G
144	RTK-Inhibitor + Trametinib	4	Colorectal Cancer	G469E
145	Trametinib	3A	Melanoma	L597V
146	Dabrafenib + Trametinib	1	Non-Small Cell Lung Cancer	V600K
147	Vemurafenib, Dabrafenib	2A	Non-Small Cell Lung Cancer	V600R
148	RTK-Inhibitor + Trametinib	4	Colorectal Cancer	S467L
149	RTK-Inhibitor + Trametinib	4	Colorectal Cancer	G596R
150	RTK-Inhibitor + Trametinib	4	Colorectal Cancer	G596D
151	RTK-Inhibitor + Trametinib	4	Colorectal Cancer	D287H
152	Dabrafenib + Trametinib	1	Non-Small Cell Lung Cancer	V600G
153	RTK-Inhibitor + Trametinib	4	Colorectal Cancer	N581I
154	RTK-Inhibitor + Trametinib	4	Non-Small Cell Lung Cancer	V459L
155	RTK-Inhibitor + Trametinib	4	Colorectal Cancer	G466E
156	Trametinib	4	Melanoma	G464E
157	Trametinib	4	Melanoma	G469A
158	RTK-Inhibitor + Trametinib	4	Colorectal Cancer	G466A
159	RTK-Inhibitor + Trametinib	4	Colorectal Cancer	D594H
160	RTK-Inhibitor + Trametinib	4	Colorectal Cancer	N581S
161	RTK-Inhibitor + Trametinib	4	Non-Small Cell Lung Cancer	D594H
162	Vemurafenib, Dabrafenib, Dabrafenib + Trametinib, Vemurafenib + Cobimetinib, Trametinib	1	Melanoma	V600R
163	Vemurafenib, Dabrafenib, Dabrafenib + Trametinib, Vemurafenib + Cobimetinib, Trametinib	1	Melanoma	V600D
164	Dabrafenib + Trametinib	1	Non-Small Cell Lung Cancer	V600E
165	RTK-Inhibitor + Trametinib	4	Non-Small Cell Lung Cancer	F595L
166	RTK-Inhibitor + Trametinib	4	Non-Small Cell Lung Cancer	D594A
167	RTK-Inhibitor + Trametinib	4	Non-Small Cell Lung Cancer	G596D
168	Vemurafenib, Dabrafenib, Dabrafenib + Trametinib, Vemurafenib + Cobimetinib, Trametinib	1	Melanoma	V600E
169	Trametinib	4	Melanoma	G469V
170	Trametinib	3A	Melanoma	L597S
171	Trametinib	3A	Melanoma	K601E
172	RTK-Inhibitor + Trametinib	4	Non-Small Cell Lung Cancer	D287H
173	RTK-Inhibitor + Trametinib	4	Non-Small Cell Lung Cancer	G466V
174	LTT462, BVD-523, KO-947	4	All Tumors	Oncogenic Mutations
175	Vemurafenib	1	Histiocytosis	V600K
176	RTK-Inhibitor + Trametinib	4	Colorectal Cancer	V459L
177	RTK-Inhibitor + Trametinib	4	Non-Small Cell Lung Cancer	G469E
178	RTK-Inhibitor + Trametinib	4	Colorectal Cancer	D594G
179	Dabrafenib + Trametinib	1	Non-Small Cell Lung Cancer	V600R
180	Dabrafenib + Trametinib	1	Non-Small Cell Lung Cancer	V600M
181	RTK-Inhibitor + Trametinib	4	Non-Small Cell Lung Cancer	G596R
182	RTK-Inhibitor + Trametinib	4	Non-Small Cell Lung Cancer	S467L
183	Trametinib	4	Melanoma	G464V
184	RTK-Inhibitor + Trametinib	4	Non-Small Cell Lung Cancer	D594N
185	Vemurafenib, Dabrafenib	2A	Non-Small Cell Lung Cancer	V600K
186	Vemurafenib	1	Histiocytosis	V600G
187	AP32788	4	Non-Small Cell Lung Cancer	S768I
188	Afatinib, Erlotinib, Gefitinib	1	Non-Small Cell Lung Cancer	S768I
189	Afatinib, Erlotinib, Gefitinib	1	Non-Small Cell Lung Cancer	L833V
190	Erlotinib, Afatinib, Gefitinib	1	Non-Small Cell Lung Cancer	L858R
191	Afatinib, Erlotinib, Gefitinib	1	Non-Small Cell Lung Cancer	G719A
192	Erlotinib, Afatinib, Gefitinib	1	Non-Small Cell Lung Cancer	E709K
193	Erlotinib, Afatinib, Gefitinib	1	Non-Small Cell Lung Cancer	A750P
194	AP32788	4	Non-Small Cell Lung Cancer	Exon 20 insertion
195	Afatinib, Erlotinib, Gefitinib	1	Non-Small Cell Lung Cancer	G719C
196	AP32788	4	Non-Small Cell Lung Cancer	L861R
197	Erlotinib, Afatinib, Gefitinib	R1	Non-Small Cell Lung Cancer	T790M
198	Osimertinib	1	Non-Small Cell Lung Cancer	T790M
199	Erlotinib, Afatinib, Gefitinib	1	Non-Small Cell Lung Cancer	EGFR-KDD Fusion
200	Erlotinib, Afatinib, Gefitinib	R1	Non-Small Cell Lung Cancer	Exon 20 insertion
201	Afatinib, Erlotinib, Gefitinib	1	Non-Small Cell Lung Cancer	Exon 19 insertion
202	Erlotinib, Afatinib, Gefitinib	1	Non-Small Cell Lung Cancer	Exon 19 deletion/insertion
203	Erlotinib, Afatinib, Gefitinib	1	Non-Small Cell Lung Cancer	Exon 19 deletion
204	Erlotinib, Afatinib, Gefitinib	1	Non-Small Cell Lung Cancer	L861R
205	Afatinib, Erlotinib, Gefitinib	1	Non-Small Cell Lung Cancer	A763_Y764insFQEA
206	Erlotinib, Afatinib, Gefitinib	1	Non-Small Cell Lung Cancer	E709_T710delinsD
207	Afatinib, Erlotinib, Gefitinib	1	Non-Small Cell Lung Cancer	L747P
208	Erlotinib, Afatinib, Gefitinib	1	Non-Small Cell Lung Cancer	L861Q
209	Afatinib, Erlotinib, Gefitinib	1	Non-Small Cell Lung Cancer	G719S
210	AP32788	4	Non-Small Cell Lung Cancer	G719A
211	Sonidegib, Vismodegib	3A	Skin Cancer, Non-Melanoma	Truncating Mutations
212	Sonidegib	3A	Embryonal Tumor	Truncating Mutations
213	Tipifarnib	3A	Head and Neck Squamous Cell Carcinoma	Oncogenic Mutations
214	LTT462, Binimetinib, BVD523, Trametinib	4	All Tumors	Oncogenic Mutations
215	Cabozantinib	2A	Renal Cell Carcinoma	Amplification
216	Cabozantinib, Capmatinib	3A	Non-Small Cell Lung Cancer	Y1003N
217	Crizotinib	2A	Non-Small Cell Lung Cancer	D1010H
218	Crizotinib	2A	Non-Small Cell Lung Cancer	963_D1010splice
219	Crizotinib	2A	Non-Small Cell Lung Cancer	X1007_splice
220	Cabozantinib, Capmatinib	3A	Non-Small Cell Lung Cancer	D1010H
221	Crizotinib	2A	Non-Small Cell Lung Cancer	Y1003N
222	Crizotinib	2A	Non-Small Cell Lung Cancer	981_1028splice
223	Cabozantinib, Capmatinib	3A	Non-Small Cell Lung Cancer	X1009_splice
224	Cabozantinib, Capmatinib	3A	Non-Small Cell Lung Cancer	D1010N
225	Cabozantinib, Capmatinib	3A	Non-Small Cell Lung Cancer	963_D1010splice
226	Crizotinib	2A	Non-Small Cell Lung Cancer	Amplification
227	Cabozantinib, Capmatinib	3A	Non-Small Cell Lung Cancer	X963_splice
228	Crizotinib	2A	Non-Small Cell Lung Cancer	X1006_splice
229	Cabozantinib, Capmatinib	3A	Non-Small Cell Lung Cancer	X1008_splice
230	Crizotinib	2A	Non-Small Cell Lung Cancer	X963_splice
231	Cabozantinib, Capmatinib	3A	Non-Small Cell Lung Cancer	D1010Y
232	Crizotinib	2A	Non-Small Cell Lung Cancer	D1010N
233	Crizotinib	2A	Non-Small Cell Lung Cancer	X1008_splice
234	Cabozantinib, Capmatinib	3A	Non-Small Cell Lung Cancer	X1006_splice
235	Crizotinib	2A	Non-Small Cell Lung Cancer	D1010Y
236	Cabozantinib, Capmatinib	3A	Non-Small Cell Lung Cancer	981_1028splice
237	Cabozantinib, Capmatinib	3A	Non-Small Cell Lung Cancer	X1007_splice
238	Crizotinib	2A	Non-Small Cell Lung Cancer	X1009_splice
239	Crizotinib, Ceritinib	2A	Inflammatory Myofibroblastic Tumor	Fusions
240	Crizotinib, Brigatinib, Alectinib, Ceritinib	1	Non-Small Cell Lung Cancer	Fusions
241	TK216	4	Soft Tissue Sarcoma	Fusions
242	Sorafenib	3A	Acute Myeloid Leukemia	FLT3 internal tandem duplications
243	Ruxolitinib	3A	Leukemia	PCM1-JAK2 Fusion
244	AZD6482 + Alpelisib	4	Breast Cancer	Oncogenic Mutations
245	GSK2636771, AZD8186	4	All Tumors	Oncogenic Mutations
246	Crizotinib	1	Non-Small Cell Lung Cancer	Fusions
247	Imatinib	1	Myelodysplasia	Fusions
248	Imatinib	1	Dermatofibrosarcoma Protuberans	Fusions
249	Imatinib	1	Myeloproliferative Neoplasm	Fusions
250	Nilotinib, Imatinib, Ponatinib	4	All Tumors	Oncogenic Mutations
251	Olaparib	4	Prostate Cancer	Truncating Mutations
252	Olaparib	4	Prostate Cancer	N2875K
253	Olaparib	4	Prostate Cancer	R3008C
254	Cobimetinib, Trametinib	3A	Melanoma	Oncogenic Mutations
255	Cobimetinib, Trametinib	3A	Low-Grade Serous Ovarian Cancer	Oncogenic Mutations
256	Cobimetinib, Trametinib	3A	Non-Small Cell Lung Cancer	Oncogenic Mutations
257	Cobimetinib, Trametinib	3A	Histiocytic Disorder	Oncogenic Mutations
258	Imatinib	1	Leukemia	FIP1L1-PDGFRA Fusion
259	Imatinib	1	Myeloproliferative Neoplasm	Fusions
260	Dasatinib	2A	Gastrointestinal Stromal Tumor	D842V
261	Imatinib	1	Myelodysplasia	Fusions
262	Imatinib	2A	Gastrointestinal Stromal Tumor	Oncogenic Mutations
263	Imatinib	R1	Gastrointestinal Stromal Tumor	D842V
